Trial record 1 of 1 for:
NCT00854256
Trabeculectomy Versus Canaloplasty to Treat Glaucoma
This study is currently recruiting participants.
Verified April 2013 by University of Cologne
Sponsor:
University of Cologne
Collaborator:
iScience Interventional Corporation
Information provided by:
University of Cologne
ClinicalTrials.gov Identifier:
NCT00854256
First received: March 2, 2009
Last updated: April 12, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to investigate pressure lowering effect of two surgical methods canaloplasty and trabeculectomy in patients with open angle glaucoma, in which under local pressure lowering therapy the progression of the disease could not be stopped, and thus a pressure lowering surgical intervention is necessary. The risks in the postoperative course in Canaloplasty in the literature as lower than for the trabeculectomy with mitomycin-C. Conversely, large glaucoma centers questioning the effectiveness of permanent pressure lowering of canaloplasty. Precisely this question is investigated in the study.
| Condition | Intervention |
|---|---|
|
Glaucoma |
Procedure: Canaloplasty Procedure: Trabeculectomy with mitomycin C |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparison of Canaloplasty and Trabeculectomy in Patients With Open Angle Glaucoma and Inadequate Local Eye Pressure Lowering Therapy - a Prospective, Randomized Study |
Resource links provided by NLM:
Genetics Home Reference related topics:
early-onset glaucoma
MedlinePlus related topics:
Glaucoma
Drug Information available for:
Mitomycin
U.S. FDA Resources
Further study details as provided by University of Cologne:
Primary Outcome Measures:
- Eye pressure [ Time Frame: Within 12 month after surgery ] [ Designated as safety issue: No ]Eye pressure is measured after 1 month, 2 months, 3 months, 6 months, 9 months, and 12 months after surgery.
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | May 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Canaloplasty |
Procedure: Canaloplasty
Canaloplasty surgery
|
| Active Comparator: Trabeculectomy with mitomycin C |
Procedure: Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C surgery
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients with open angle glaucoma and excavation of 0.4 - 0.8
- 60 eyes of 60 patients (30 patients for trabeculectomy, 30 patients for Canaloplasty) The ratio of female / male is not involved.
- Eye pressure under local therapy: 20mmHg and above (corrected with pachymetry table).
- Local drug therapy: at least 2 eye pressure lowering ingredients or absolute intolerance to preservatives or eye drops.
- general anesthesia possible.
- The operation must be signed by the surgeon as a state-of-the-art performed without complication to be evaluated. If the operation does not meet this criterion, the patient is excluded from the study.
Exclusion Criteria:
- all patients are not included in the group of inclusion criteria, or:
- Phenprocoumon therapy.
- operation is not done state-of-the-art.
- after the surgery: additional eye pressure lowering surgery, cataract surgery, keratoplasty, laser surgery in the anterior eye segment (except suture lysis after trabeculectomy)
- Uveitis, or possible inflammation of the eye
- Previous eye pressure lowering operations or laser interventions
- Corneal Refractive Surgery (pseudophakia allowed)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00854256
Contacts
| Contact: Gerhard Welsandt, MD | +49-221-478-0 | g.welsandt@uni-koeln.de |
Locations
| Germany | |
| Centre of Ophthalmology, University of Cologne | Recruiting |
| Cologne, NRW, Germany, 50924 | |
Sponsors and Collaborators
University of Cologne
iScience Interventional Corporation
More Information
No publications provided
| Responsible Party: | Gerhard Welsandt, MD, University of Cologne |
| ClinicalTrials.gov Identifier: | NCT00854256 History of Changes |
| Other Study ID Numbers: | iScience-022-CG |
| Study First Received: | March 2, 2009 |
| Last Updated: | April 12, 2013 |
| Health Authority: | Germany: Ethics Commission Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by University of Cologne:
|
glaucoma |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases Mitomycins Mitomycin Antibiotics, Antineoplastic Antineoplastic Agents |
Therapeutic Uses Pharmacologic Actions Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Alkylating Agents |
ClinicalTrials.gov processed this record on May 22, 2013